Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.


Adenosquamous Carcinoma of the Lung (ASC)

In recent years, there has been a growing interest in understanding the biology and developing effective therapies for adenosquamous carcinoma of the lung (ASC). Our company, a leader in the field of drug and therapy development, is at the forefront of research and innovation in the battle against ASC.

Introduction to ASC

Adenosquamous carcinoma of the lung (ASC), also known as adenosquamous lung carcinoma (AdSqLC), is a rare and aggressive form of lung cancer characterized by the presence of both squamous cell carcinoma (SCC) and adenocarcinoma (AC) components within the tumor. It accounts for approximately 0.4-4% of all lung carcinomas. ASC is distinct from purely squamous cell carcinoma or adenocarcinoma due to its unique histological features and aggressive behavior.

Pathogenesis of ASC

Several risk factors have been identified that may contribute to the development of this rare lung cancer subtype. These include:

  • Smoking: Cigarette smoking is the leading cause of lung cancer, including ASC. The carcinogens present in tobacco smoke can trigger genetic mutations and cellular changes that lead to the development of ASC.
  • Environmental Factors: Exposure to certain environmental pollutants, such as asbestos, radon, and air pollution, has been associated with an increased risk of developing lung cancer, including ASC.
  • Genetic Predisposition: Some individuals may have genetic predispositions that make them more susceptible to the development of ASC. Mutations in genes such as EGFR, KRAS, and TP53 have been implicated in the pathogenesis of ASC.
Fig.1 Representative histological images of AC-predominant (a, b)/SCC-predominant(c, d) ASC of the lung.Fig.1 Representative histological images of AC-predominant (a, b)/SCC-predominant(c, d) ASC of the lung. (Liu, Yangli, et al., 2020)

Targeted Therapies for Genetic Tumor Syndromes

  • Targets of ASC Therapy

EGFR (Epidermal Growth Factor Receptor)

Mutations in the EGFR gene have been implicated in the pathogenesis of ASC. Therefore, therapies targeting EGFR signaling pathways have shown promise in ASC.

KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog)

Mutations in the KRAS gene are commonly observed in lung cancers, including ASC. Targeting KRAS-driven pathways holds potential for the development of effective therapies for ASC.

TP53 (Tumor Protein 53)

TP53 mutations are frequently found in ASC and are associated with a poor prognosis. Strategies aimed at restoring normal TP53 function or targeting alternative pathways affected by TP53 mutations are under investigation.

  • Types of ASC Therapy
Targeted Therapies

Targeted Therapies

Targeted therapies aim to specifically inhibit the activity of mutated genes or proteins that drive the growth and survival of ASC cells. EGFR inhibitors, such as gefitinib and erlotinib, have shown efficacy in ASC with EGFR mutations. Similarly, KRAS inhibitors and other targeted agents are being investigated in studies.



Immunotherapies, such as immune checkpoint inhibitors, have transformed the therapeutic landscape for lung cancer. These therapies enhance the body's immune response against cancercells by blocking immune checkpoint proteins like PD-1 or PD-L1.

Small Molecule Drugs

Small Molecule Drugs

Small molecule drugs remain an important therapy option for ASC, particularly in advanced or metastatic cases. Combination chemotherapy regimens, such as platinum-based agents combined with taxanes or pemetrexed, can be effective in controlling tumor growth and improving outcomes.

Our Services

As our understanding of the biology of lung adenosquamous carcinoma (ASC) advances, the development of targeted therapies has become more possible. Our company is at the forefront of therapeutic development for ASC, employing cutting-edge technologies and multidisciplinary approaches to accelerate the discovery and development of diagnostics as well as innovative therapies.

Our Therapy Development Platforms

Our company focuses on the development of animal models to mimic the characteristics of ASC. These models, as well as different species of experimental animals, enable us to provide complete preclinical research services, including drug safety evaluation as well as pharmacokinetic analysis.

Animal Models of ASC

If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Liu, Yangli, et al. "Adenocarcinomatous-predominant subtype associated with a better prognosis in adenosquamous lung carcinoma." BMC cancer 20 (2020): 1-7.
  • Li, Chenghui, and Hongyang Lu. "Adenosquamous carcinoma of the lung." OncoTargets and therapy (2018): 4829-4835.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions

Copyright © Protheragen. All rights reserves.